Exhibit 10.9


 


Shuttle
Pharmaceuticals, Inc.


1
Research Ct. Suite 450 ● Rockville, MD 20850 ● TEL (240) 403-4212 ● FAX (301) 519-8001


 


 


MATERIALS
TRANSFER AGREEMENT


 


This
Material Transfer Agreement (“Agreement”) is hereby made by and between the GeorgeWashington University (hereinafter
“Recipient”) and Shuttle Pharmaceuticals, Inc, Rockville, MD (hereinafter “Provider”) upon request from
Recipient for the following material (hereinafter “Material”) more particularly described below:


 


[DESCRIPTION
OF MATERIAL]


 


Recipient
and Provider hereby agree to conform to the following terms related to transfer of Material: Small molecule ATM activator/HDAC inhibitor
and selective HDAC inhibitor


 


1.
The above-described Material is the property of the Provider and is made available as a service to the research
community.


 


 2. The Material is not intended for and will not be used in human subjects.




 


 3. The Material will be used for teaching or not-for-profit research purposes only.




 


4.
The Material will not be distributed further to others without the Provider’s prior express written consent. The Recipient
shall refer any third-party request for the Material to the Provider.


 


5. The Recipient agrees to acknowledge the source of the Material in any publication reporting its use.




 


6.
Any Material delivered pursuant to this Agreement is understood to be experimental in nature and may contain hazardous properties.
The Provider makes no representations and extends no warranties of any kind, either express or implied. Unless prohibited by law,
Recipient assumes all liability for claims of damages against Recipient by third-parties which may arise from the use, storage, or
disposal of the Material except that, to the extent permitted by law, the Provider shall be liable to the Recipient when the damage
is caused by the gross negligence or willful misconduct of the Provider.


 


7.
The Recipient agrees to use the Material in compliance with all applicable state and federal statutes and regulations.


 


8.
The Material is provided at no cost or with an optional transmittal fee solely to reimburse the Provider for its preparation and
distribution costs. If a fee is requested, the amount is indicated here: $        waived       .


 


Shuttle
Pharmaceuticals, LLC ● 1 Research Court, Suite 450 ● Rockville, MD 20850


 




    	 



     


    

 


PROVIDER
INFORMATION AND AUTHORIZED SIGNATURE:


 


	Date:	 	 	 
	 	 	 	Anatoly
                                    Dritschilo, MD

                                    CEO

                                    Shuttle
                                    Pharmaceuticals, Inc

                                    One
                                    Research Court, Suite 450

                                    240-403-4212

                                    anatoly.dritschilo@shuttlepharma.org

	 	 	 
	 	 	Provider





 


RECIPIENT
INFORMATION AND AUTHORIZED SIGNATURE:


 


	Date: 	4-24-2017	 	
	 	 	Charles
                                            T. Maples

    Sr.
    Contracting Officer, Sponsored Projects

    Office of the Vice President for Research

    George Washington University

    2121
    Eye Street, NW, Suite 601

    Washington, DC 20052 USA

     

    Recipient




 


	READ AND ACKNOWLEDGED

                                                                                 

                                                                                          4/24/2017
	 	 
		 	

    Alejandro
    Villagra, PhD

    Assistant Professor

    Cancer
    Biology Program, GW Cancer Center

     

    Department
    of Biochemistry and Molecular Medicine

    School of Medicine and Health Sciences

    The
    George Washington University

    800
    22nd St NW, Suite 8880 | Washington, DC 20052

    (202)
    994 9547 | avillagra@gwu.edu

     

    Recipient




 






    	2



     


    

 


EXHIBIT
A – Research Plan


 


Dr.
Villagra will write in vitro assays related to the Materials. No in vivo studies are contemplated in this MTA.


 




    	3